Publications by authors named "Enrique Baez-De la Fuente"
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Leuk Lymphoma
December 2019
Article Synopsis
- - Ruxolitinib has been approved for treating polycythemia vera patients who can't tolerate or are resistant to hydroxyurea, based on findings from the RESPONSE studies.
- - In a phase 3b study involving 161 patients, nearly 38% experienced adverse events that required dose adjustments, with anemia and thrombocytosis as the most common issues.
- - After 24 weeks, 45.3% of participants achieved hematocrit control, 18% had hematologic remission, and 86.7% saw a significant reduction in spleen size, with safety and efficacy similar to previous studies.
The purpose of this study was to evaluate DNA damage in the whole genome of peripheral blood leukocytes from patients with acute myeloid leukemia (AML) compared with a control group using DNA breakage detection-fluorescent in situ hybridization (DBD-FISH). Our results suggest that the DNA damage detected in patients with newly diagnosed AML was similar to that observed for the controls; this might be explained by the stimulation of a repair pathway by the pathogenesis itself. These findings indicate that inhibiting the repair pathway could be proposed to enhance the efficacy of chemotherapy.
View Article and Find Full Text PDFBackground: Chronic myeloid leukemia is a myeloproliferative disease characterized by the Philadelphia chromosome and with this, the chimeric protein BCR-ABL. The first-line treatment is imatinib, a tyrosine kinase inhibitor, that has showed good results, but with a significant percentage of treatment failure. This failure has led to second-generation tyrosine kinase inhibitors as second-line treatment such as dasatinib.
View Article and Find Full Text PDF[Pregnancy and myeloid leukemia treated with imatinib. Development and monitoring of a patient].
Rev Med Inst Mex Seguro Soc
October 2015
Background: Imatinib has changed the natural history of chronic myeloid leukemia. There are women with chronic myeloid leukemia in reproductive age with pregnancy desires. The aim of this case was to report the course and outcome of pregnancy in a patient with chronic myeloid leukemia diagnosis treated with imatinib.
View Article and Find Full Text PDF[Nilotinib in patients with chronic myeloid leukemia without response to imatinib].
Rev Med Inst Mex Seguro Soc
October 2015
Background: Resistance and intolerance to imatinib in patients with chronic myeloid leukemia requires alternative therapies. Nilotinib provides a choice as a second-line treatment. The objective of this report was to show the results of a group of patients with chronic myeloid leukemia who received nilotinib as a second-line treatment.
View Article and Find Full Text PDFIntroduction: Our aim was to characterize the cytogenetic profile that displays a certain phase of chronic myelogenous leukemia (CML), offering new directions for investigation of the etiology to the molecular level. In Mexico, data does not exist in this regard; thus, the objective of the present study was to determine cytogenetic alterations in 56 Mestizo Mexican patients with LMC.
Design: Cross-sectional study (diagnosis and stage) was carried out.